Article

Nanobodies as allosteric modulators of Parkinson’s disease-associated LRRK2

2021-08-30

Abstract excerpt

Mutations in the gene coding for Leucine-Rich Repeat Kinase 2 (LRRK2) are a leading cause of the inherited form of Parkinson’s disease (PD), while LRRK2 overactivation is also associated with the more common idiopathic form of PD. LRRK2 is a large multi-domain protein, including a GTPase as well as a Ser/Thr protein kinase domain. Common disease-causing mutations increase LRRK2 kinase activity, presenting LRRK2 as...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4db92cb5-22b9-52c9-b74b-7a15cc7d9dcf
DOI: 10.1101/2021.08.30.458082

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Nanobodies as allosteric modulators of Parkinson’s disease-associated LRRK2DOI 10.1101/2021.08.30.458082Read

Allosteric inhibition of LRRK2, where are we now.Semantic proximity Read

Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease ModelsSemantic proximity Read

Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s diseaseSemantic proximity Read

Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to dateSemantic proximity Read

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.Semantic proximity Read

LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.Semantic proximity Read

Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)Semantic proximity Read

The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.Semantic proximity Read

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).Semantic proximity Read

Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.Semantic proximity Read

Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.Semantic proximity Read

Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?Semantic proximity Read